Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Natural Resource Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Christopher Loe who wrote (16370)	10/14/2004 1:17:19 PM
From: schzammm	Read Replies (1) \| Respond to of 108677

OFF TOPIC: Chris, I am playing GENR in the "wet" age-related macular degeneration (AMD) area. Genr has three clinical trials for AMD and at least one of them is with QLTI's Visudyne. Should get some results on one of the trials by the first week of Nov. at the latest. Both QLTI and GENR up this morning on Alcon's failure of their AMD drug. MSI-1256F-208 is the second Phase II trial designed to evaluate the effects of three different doses of squalamine in combination with an initial Visudyne® treatment in 45 patients with AMD. Specifically, this study will evaluate the safety and effects of systemically administered squalamine before and after photodynamic therapy with Visudyne®. Based on its mechanism of action, this squalamine pretreatment has the potential to improve the effect of Visudyne®, and squalamine follow up treatment may inhibit the detrimental effects of the VEGF 'burst' that commonly occurs after Visudyne® treatment.